Consistent with the in vitro data, regorafenib dramatically eliminated the phosphorylation of p-AKT (S473) and p-S6 (S235/236) in the tumor cells from the treatment group (Figure 5E, 5F). This evidence concerns the gene AKT1 and neoplasm.